Rheumatologist Salary Guide 2026: Biologic Infusion Revenue, wRVU & Pay by Setting

Rheumatology is a cognitive specialty that has quietly developed one of the more differentiated private-practice income models in internal medicine — primarily through biologic medication infusion centers and the buy-and-bill revenue that comes with managing IV biologics in office. In 2026, employed rheumatologists typically earn $240,000–$320,000, while private practice rheumatologists with established infusion programs can reach $350,000–$420,000 or higher. This guide covers salary benchmarks by setting, the economics of biologic infusion revenue, wRVU productivity patterns, and the supply-demand dynamics that make rheumatology a shortage specialty in most U.S. markets.

Rheumatologist salary by setting

Practice model is the primary compensation differentiator in rheumatology, more so than in most cognitive specialties, because of the infusion revenue gap between employed and private practice settings:

• Employed rheumatologist (health system / large group): $240,000–$320,000; salary + quality bonus + wRVU productivity incentive; health system captures most biologic infusion revenue; employed model growing as hospital systems acquire independent rheumatology practices, often reducing total physician income in the process
• Private practice rheumatology group (independent): $280,000–$420,000; the income premium over employed is almost entirely driven by in-office biologic infusion revenue; groups that have invested in infusion infrastructure (infusion chairs, nursing staff, J-code billing) and built the patient volume to justify it consistently outpay employed models
• Academic rheumatology (medical school faculty): $210,000–$280,000; lowest-paying setting for most rheumatologists; offset by NIH grant supplementation for investigators, teaching mission, and access to complex disease referrals (SLE, vasculitis, inflammatory myopathy) that build academic subspecialty expertise
• Pediatric rheumatology: $195,000–$265,000; among the most severe physician shortages in any subspecialty — ACGME pediatric rheumatology fellowship training slots are very limited and fill at a fraction of need; pay is lower than adult rheumatology due to pediatric E&M reimbursement dynamics but demand vastly exceeds supply
• Telemedicine / remote rheumatology: $200,000–$285,000; growing segment for CKD-geographic-shortage areas; primary utility is follow-up management and medication titration; new patient evaluations and MSK ultrasound still require in-person

Biologic infusion revenue and buy-and-bill economics

The most important income driver distinguishing private practice rheumatologists from their employed peers is the biologic medication buy-and-bill model. Understanding the economics is essential for evaluating any rheumatology compensation package:

• How buy-and-bill works in rheumatology: The practice purchases biologic medications directly from the manufacturer or a specialty distributor (at Average Sales Price, ASP), administers them in the office infusion center, and bills the payer at ASP + markup (Medicare is ASP + 6%; commercial payers vary, often higher); the difference is the practice's margin
• Common IV biologics in rheumatology infusion: Abatacept (Orencia), rituximab (Rituxan), tocilizumab (Actemra), belimumab (Benlysta), infliximab/biosimilars, natalizumab (for overlap syndromes); each generates a J-code claim with margin potential
• Infusion revenue contribution: A mid-size private practice rheumatology group with 2–3 physicians and an established infusion center running 15–25 chairs/week can generate $200,000–$500,000+ per year in infusion-derived practice revenue above the physician's clinical E&M income; this is shared among physician owners
• Commercial payer dynamics: White-bagging and brown-bagging mandates (where PBM requires patients to use specialty pharmacy rather than in-office purchase) are reducing buy-and-bill margin in some markets and with some payers; rheumatology practices actively negotiate against these clauses in payer contracts
• Biosimilar impact: Biosimilar entry for infliximab, rituximab, and adalimumab has reduced per-infusion drug cost, reducing buy-and-bill margin per unit but also making infusion economics more accessible for smaller practices

wRVU productivity in rheumatology

Rheumatology is predominantly an E&M-driven specialty with a growing procedural component:

• Typical wRVU rate: $48–$65/unit; similar range to other internal medicine subspecialties; private groups often negotiate higher rates
• Full-time outpatient rheumatologist: 3,800–5,000 wRVUs/year; mix of new and established patient visits; infusion management adds J-code revenue but limited additional wRVU volume for the administering physician (nursing-administered with physician oversight)
• MSK ultrasound and joint procedures: US-guided joint aspirations (CPT 76882 + 20600 series), soft tissue injections, and synovial biopsy guidance add meaningful incremental wRVU; experienced MSK ultrasound rheumatologists perform 5–15 guided procedures/week, contributing $15,000–$40,000 in additional annual wRVU value
• Inpatient rheumatology consultation: Flare management, vasculitis, inflammatory arthritis crisis, drug toxicity monitoring; inpatient consult volume adds 500–1,200 wRVUs/year for rheumatologists covering hospital-based practices

Musculoskeletal ultrasound and procedural revenue

Musculoskeletal (MSK) ultrasound has become an increasingly important skill for procedurally-oriented rheumatologists. US-guided joint injections and aspirations improve clinical accuracy and generate additional billing versus unguided procedures:

• MSK US certification: ARMSA (Accreditation in Rheumatologic Musculoskeletal Sonography) from the ACR/AIUM or equivalent; increasingly preferred by competitive private practice groups
• Revenue contribution: Each US-guided injection (wrist, knee, shoulder, small joints) generates a separate image guidance code (CPT 76882); 10 guided procedures/week × 48 weeks × ~$75 margin/procedure = roughly $36,000/year in additional revenue, plus improved patient satisfaction and outcomes

Geographic variation in rheumatology compensation

Rheumatology shortages are nationwide, but compensation varies by market and practice model access:

• Sun Belt / high-growth markets (FL, TX, AZ, NC): $290,000–$400,000; growing patient population with RA/PsA/lupus prevalence; private group practices with established infusion centers dominate
• Northeast / Mid-Atlantic: $270,000–$370,000; high academic center concentration suppresses private practice expansion; commercial payer white-bagging mandates more prevalent
• Midwest / rural: $260,000–$380,000 when shortage-area premiums are included; some rural health systems offering $50,000–$80,000 sign-on for the only rheumatologist within 100+ miles
• Pacific Coast: $265,000–$370,000; strong health system employment base; independent group practice growth constrained by payer landscape

What we see at Ava Health

Rheumatology is one of the most consistently requested physician specialties across our health system clients — vacancy rates are high, and the wait time to see a rheumatologist in most mid-size U.S. markets exceeds six months, which directly translates to aggressive recruiting when a facility has an open position. The compensation gap between employed health system rheumatology and well-structured private practice infusion-center models is real and often not fully disclosed in health system offer letters — we make a point of helping rheumatologist candidates in our network understand the full income comparison, including infusion economics, before accepting any offer. For new fellows in particular, the choice between a health system employed model and joining an established private group with infusion infrastructure can be worth $80,000–$130,000/year over the first decade of practice.

Related: Internal Medicine Physician Salary Guide, Endocrinologist Salary Guide, Nephrologist Salary Guide, Physician Assistant Salary Guide.